[go: up one dir, main page]

WO2006110623A3 - Toxine cholerique ciblee pour le traitement de la douleur persistante ou chronique - Google Patents

Toxine cholerique ciblee pour le traitement de la douleur persistante ou chronique Download PDF

Info

Publication number
WO2006110623A3
WO2006110623A3 PCT/US2006/013239 US2006013239W WO2006110623A3 WO 2006110623 A3 WO2006110623 A3 WO 2006110623A3 US 2006013239 W US2006013239 W US 2006013239W WO 2006110623 A3 WO2006110623 A3 WO 2006110623A3
Authority
WO
WIPO (PCT)
Prior art keywords
cholera toxin
pain
chonic
persistent
targeted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/013239
Other languages
English (en)
Other versions
WO2006110623A2 (fr
Inventor
Robert M Caudle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Florida
University of Florida Research Foundation Inc
Original Assignee
University of Florida
University of Florida Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Florida, University of Florida Research Foundation Inc filed Critical University of Florida
Publication of WO2006110623A2 publication Critical patent/WO2006110623A2/fr
Publication of WO2006110623A3 publication Critical patent/WO2006110623A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne un composé fabriqué par conjugaison d'une toxine cholérique (ou d'une sous-unité de celle-ci) à une molécule de ciblage facilitant le ciblage de la toxine cholérique sur un récepteur couplé aux protéines G spécifique sur des neurones. Les molécules de ciblage de l'invention peuvent comprendre, entre autres, une substance P, un opioïde et CGRP, ou un peptide quelconque pour lequel il existe un récepteur couplé aux protéines G. Plus particulièrement, l'invention se rapporte à la fabrication d'un composé par conjugaison d'une substance P à une toxine cholérique, ce composé supprimant la douleur chez un sujet tout en réduisant la mort cellulaire des neurones.
PCT/US2006/013239 2005-04-09 2006-04-10 Toxine cholerique ciblee pour le traitement de la douleur persistante ou chronique Ceased WO2006110623A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66980205P 2005-04-09 2005-04-09
US60/669,802 2005-04-09

Publications (2)

Publication Number Publication Date
WO2006110623A2 WO2006110623A2 (fr) 2006-10-19
WO2006110623A3 true WO2006110623A3 (fr) 2006-12-21

Family

ID=37087584

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/013239 Ceased WO2006110623A2 (fr) 2005-04-09 2006-04-10 Toxine cholerique ciblee pour le traitement de la douleur persistante ou chronique

Country Status (1)

Country Link
WO (1) WO2006110623A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10851378B2 (en) * 2015-07-16 2020-12-01 Saint Louis University Methods of treating pain using anti-GPR160 antibodies

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4664911A (en) * 1983-06-21 1987-05-12 Board Of Regents, University Of Texas System Immunotoxin conjugates employing toxin B chain moieties
US5169933A (en) * 1988-08-15 1992-12-08 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
US6022950A (en) * 1984-06-07 2000-02-08 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
US6545126B1 (en) * 1999-03-18 2003-04-08 Wisconsin Alumni Research Foundation Chimeric toxins

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4664911A (en) * 1983-06-21 1987-05-12 Board Of Regents, University Of Texas System Immunotoxin conjugates employing toxin B chain moieties
US6022950A (en) * 1984-06-07 2000-02-08 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
US5169933A (en) * 1988-08-15 1992-12-08 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
US6545126B1 (en) * 1999-03-18 2003-04-08 Wisconsin Alumni Research Foundation Chimeric toxins

Also Published As

Publication number Publication date
WO2006110623A2 (fr) 2006-10-19

Similar Documents

Publication Publication Date Title
NL300943I2 (nl) Ertugliflozine, desgewenst in kristalvorm, met name als co-kristal met L-pyroglutaminezuur, met name Ertugliflozin L-pyroglutamine zuur
WO2008036682A3 (fr) Traitement des troubles hépatiques par l'administration de conjugués de protéine associée au récepteur (rap)
CA2796722C (fr) Compositions et procedes permettant l'administration selective de molecules d'oligonucleotides a des types de neurones specifiques
WO2007011941A3 (fr) Anticorps neutralisants anti-b7rp1 humains
WO2008095040A3 (fr) Analogues de 2-5a et leurs procédés d'utilisation
WO2008063511A3 (fr) Méthodes de traitement de la maladie de pompe
WO2006074451A3 (fr) Molecules chimeriques ciblees pour la therapie du cancer
BRPI0410731A (pt) composto, composição farmacêutica, métodos para agonizar o receptor mc4, para tratar obesidade, para tratar diabetes melito e para tratar disfunção sexual masculina e/ou feminina em um mamìfero, e, uso de um composto
NO20075245L (no) Eliminasjon av heterogen eller blandet cellepopulasjon i tumorer
WO2007105027A8 (fr) Médicaments anticancéreux conjugués à un anticorps au moyen d'un lieur dissociable par une enzyme
WO2009009441A3 (fr) Complexe s'auto-assemblant pour cibler des agents chimiques sur des cellules
WO2005092392A3 (fr) Medicaments psychotropes conjugues et leurs utilisations
WO2010136508A3 (fr) Ciblage de cellules souches
WO2008024371A3 (fr) Inhibiteurs de transporteurs multimédiateurs à utiliser pour le traitement de troubles du système nerveux central
WO2004062602A3 (fr) Compositions et methodes de transport biologique cible de supports moleculaires
WO2010039461A3 (fr) Procédés de synthèse et d'utilisation d'inhibiteurs de la grhéline o-acyltransférase comme agents thérapeutiques potentiels pour traiter l'obésité et le diabète
CY1113525T1 (el) Θεραπεια στοχευσης καθεψινης s
WO2009023355A3 (fr) Compositions et procédés pour réduire la toxicité de certaines toxines
WO2007064727A3 (fr) 'penetrabodies' : administration ciblee a mediation par recepteur de fragments d'anticorps fonctionnellement actifs dans le cytosol pour traiter des infections et des maladies chroniques
WO2009143345A3 (fr) Conjugués agent-protéine désactivant des acides nucléiques et leur utilisation pour traiter des troubles liés au vhc
DE502007002949D1 (de) Proteinbindende methotrexat-derivate und diese enthaltende arzneimittel
WO2010057647A3 (fr) Procédés et compositions pour le diagnostic et le traitement du diabète
WO2006110623A3 (fr) Toxine cholerique ciblee pour le traitement de la douleur persistante ou chronique
WO2006096405A3 (fr) Modulation de maladies neurodegeneratives
WO2005039589A3 (fr) Modulateurs des canaux cftr

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06740777

Country of ref document: EP

Kind code of ref document: A2